|Bid||4.3250 x N/A|
|Ask||4.8360 x N/A|
|Day's range||4.4300 - 4.4950|
|52-week range||2.4160 - 6.3040|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||08 May 2023 - 12 May 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Ocular Therapeutix (OCUL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Ocular Therapeutix ( NASDAQ:OCUL ) Full Year 2022 Results Key Financial Results Revenue: US$51.5m (up 18% from FY...
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 4% and 3.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?